Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Pleuropulmonary Disease Associated with Dopamine Agonist Therapy
Ann Neurol 30:613-616, Bhatt,M.H.,et al, 1991
Acromegaly
NEJM 322:966-977, Melmed,S., 1990
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Treatment of Advanced Parkinson Disease With Pergolide
Neurol 31:675-682, Lieberman,A.,et al, 1981
Meige Disease:Striatal Dopaminergic Preponderance
Neurol 29:1126-1130, Tolosa,E.S.,et al, 1979
Drug Therapy, Bromocriptine
NEJM 301:873-878, Parkes,D., 1979
Prolactin-Secreting Tumors & Hypogonadism in 22 Men
NEJM 299:847-852, Carter,J.N.,et al, 1978